The 165,000 square feet facility will serve as the site for Abraxis’ research and development operations once the entire revamp is completed. It was previously occupied by ICN/Valient Pharmaceuticals.
The first phase of the renovation project includes seismic upgrades and renovating the existing lab space. A new state-of-the-art laboratory for chemistry, biology, formulation and a biological safety lab will be created with the expansion.
The next phase of the Abraxis project is slated to begin soon.
